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1. Introduction 
Gadolinium ethoxybenzyl diethylenetriamineoentacetic acid (gadoxetic acid disodium, or 
Gd-EOB-DTPA, Primovist, BayerSchering, Germany) is a liver cell specific contrast agent, 
with which dynamic phase images can be obtained to assess arterial blood supply or arterial 
flow to the liver tumors, in addition to hepatobiliary phase (HBP) images that yields high 
accuracy in the detection of liver lesions [1-3]. In other words, Gd-EOB-DTPA behaves as 
non-specific extracellular contrast agent in the early dynamic phase, and as a tissue-specific 
contrast agent in later phases. Evaluation of vascularity helps in part differentiate various 
liver lesions, applying our previous experience of Gd-based extracellular contrast medium 
[4-6]. It is sometimes difficult, however, to make differentiation only from findings of Gd-
EOB-DTPA-enhanced MR (EOB-MR) images, because of insufficient arterial enhancement 
due to small dose of Gd-EOB-DTPA used (25μmol/kg), and lack of “equilibrium phase 
images” in the conventional sense of the word [1].  
On HBP images, because most of the liver lesions, except for some hepatocellular lesions, 
uptake little Gd-EOB-DTPA, they are uniformly considered to present as hypointense areas 
in contrast to the well-enhanced normal surrounding liver parenchyma [1-6]. However, it 
has already been reported that most of the liver tumors do enhance on the HBP images 
[1,5,6] possibly through several different mechanisms. Both liver metastasis and 
hepatocellular carcinoma (HCC) exhibit 20-30% higher signal intensity on HBP as compared 
to precontrast images [1,6]; the presumed mechanism for the former is contrast 
accumulation in the abundant fibrous interstitium or stroma, by similar mechanism as that 
of conventional extracellular Gd-based contrast medium [7], and that for the latter is either 
cellular uptake of Gd-EOB-DTPA by the neoplastic cells or interstitial accumulation, or both. 
Focal nodular hyperplasia (FNH) is well known to show 150% higher signal [1,6] because of 
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the characteristic cellular uptake of Gd-EOB-DTPA by the tumor. Hemangioma becomes 
50% higher in signal on HBP [1,6] possibly due to contrast retension in the blood pool in the 
sinusoidal space in the tumor.  
We therefore hypothesized that patterns of signal intensity on HBP images, when assessed 
in detail, may vary according to the types of liver masses and also that it may be of some 
help in the characterization of each entity. Thus, we conducted this study to elucidate 
whether qualitative assessment of signal intensity on HBP of Gd-EOB-DTPA-enhanced MR 
(EOB-MR) is useful in differential diagnosis of liver masses, in addition to the assessment of 
patterns of blood supply on the dynamic phase images. 
2. Materials and methods 
2.1 Patients 
Between June 2008 and November 2008, 65 patients underwent Gd-EOB-DTPA enhanced 
MR in our institute. Medical charts and radiological images, including MR and CT images, 
were retrospectively reviewed, and liver lesions were recruited according to the inclusion 
criteria as shown below. Our institutional review board approved this study without 
requiring specific informed consent for this study because of its retrospective nature. 
Inclusion criteria of the lesions are as follows: 1) image quality is not degraded due to any 
artifacts, 2) confirmation of the etiology of the lesions is obtained either pathologically or 
clinicoradiologically. Exclusion criteria were: 1) poor image quality due to artifacts, such as 
motion, respiratoy, or susceptibility artifacts (lesions visualized in the edge slices of the 
imaging slab where considerable signal drop was noted were also excluded)  2) lack of final 
confirmation according to our definition as shown below. Clinicoradiological criteria of the 
liver masses were as follows: hypovascular hepatocellular nodules (group1) were defined as 
those nodules which were detected on ultrasonography (US) in patients with hepatitis or 
cirrhosis, and showed no hypervascularity on dynamic MDCT which were obtained within 
four weeks from EOB-MR, or on dynamic phase of EOB-MR. Hypervascular hepatocellular 
carcinoma (HCC) (group 2) were defined as lesions which exhibited typical early 
enhancement and subsequent washout (lower density than the surrounding hepatic tissue 
on portal venous or equilibrium phase images) [8] on MDCT in patients with hepatitis or 
cirrhosis, or those which accumulated lipiodol after transcatheter treatment in patients who 
had previously had pathologically proven HCC. Hemangiomas (groups 3) were defined as 
those for which conventional MR or dynamic CT had shown typical findings [8,9], and 
remained unchanged over one year. Metastases (group 4) were defined as those nodules 
which progressed on the follow-up imaging studies including CT/US in patients with 
pathologically proven primary malignancies. FNH (group 5) were defined as those nodules 
which strongly enhances on the arterial phase and becomes similar density on the 
equilibrium phase images of MDCT, and also associated with at least partial uptake of 
superparamagnetic ironoxide (SPIO) confirmed on T2- or T2*-weighted MR images [8]. 
2.2 MR and CT technique 
MR examination was performed in a 1.5 T clinical unit (Achieva Nova Dual, Philips Medical 
Sytems, Netherland). T1-weighted chemical-shift gradient-echo images (CSI) were initially 
obtained under breath-holding using the following parameters; repetition time (TR) 165 
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msec, eho-time (TE) 2.3 and 4.6 msec, flip angle (FA) 75 degrees, 256 matrix and slice 
thickness/gap=7-8/1 mm. Then dynamic scan was performed using three-dimensional (3D) 
T1-weighted field-echo images with fat suppression (T1-high resolution isotropic volumetric 
excitation: THRIVE) (TR/TE/FA=4.7 msec/2.3 msec/15 degrees, 4 mm thickness with gap -
2 mm, 224 matrix) and test injection method. First, the injection rate was determined 
according to each patient as the whole amount of contrast (0.025mmol/kg) was injected at 3 
sec (fixed injection time), and additional 0.5 mL Gd-EOB-DTPA was injected at that rate for 
test injection, followed by an injection of 20 mL saline. Single-level, sequential, axial, turbo 
filed-echo (repetition time/echo time = 13.4/1.47, 60° flip angle) were performed every 1 
second for 60 seconds at the level of the center of the aorta at the level of celiac artery using 
as large a region of interest as possible. A time-signal intensity curve was generated using 
the software package on the MR imaging system. The time delay from the commencement 
of the test injection to the arrival of Gd at the abdominal aorta was recorded as arrival time 
of the aorta (Tao). According to the previous literature [10,11] and to our personal 
experience, the optimal arterial dominant phase (T) was roughly calculated using the 
following formula: T = Tao + 9 – 1/2 (acquisition time). Dynamic MR scanning was 
performed with THRIVE before and at T, T + 30, 90, and 240 seconds after the beginning of 
bolus administration of Gd-EOB-DTPA. 
Subsequently, two types of T2-weighted images are obtained. First, tubo-spin-echo sequence 
with breath-holding (TR/TE/echo-train=10000/120/59, slice thickness/gap=7-8/1 mm) and 
then, 3D T2-weighted imaging with fat saturation (VISTA; TR/TE/echo-train=2000/99/79) 
was performed with respiratory navigation; slice thickness and gap=3 and -1.5mm, scan 
time approximately 8 min). Then, diffusion-weighted images were obtained with 
TR/TE/FA=1500/72/90 degree, b factors 0 and 1000, 3NEX, and respiratory navigation. In 
15 minutes, hepatocellular phase images were obtained with THRIVE in the axial and 
coronal direction, the same sequence as one used for the dynamic study.  
CT was obtained with a 64-row multidetector CT (Aquilion 64, Toshiba, Tokyo, Japan) with 
the following parameters; 120kVp, auto-mAs, 0.5 mmx64, pitch 53, reconstruction 2 mm 
thickness. After unenhanced scanning of the upper abdomen, 600 mgI/kg iodinated contrast 
medium (Iopamiron 370, Bayer-Schering, Germany) was injected in 30 sec via superficial 
venous branches of the upper extremities, and arterial dominant phase (40 sec delay or 
delay determined by bolus tracking method), portal phase (70 sec delay), and equilibrium 
phase (240 sec delay) imaged were obtained. 
2.3 Assessment 
Signal intensity of the liver lesion on HBP was qualitatively graded into five categories 
using surrounding non-tumorous liver parenchyma and the inferior vena cava (IVC) as 
reference tissue; H (higher than the surrounding liver), I (similar to the liver), L1 (lower 
than the liver, and higher than IVC), L2 (similar to IVC), and L3 (lower than IVC). Visual 
comparison of the mass to IVC was made primarily within the same slice as the target 
mass is located, but when IVC is too small in size and hard to evaluate its signal intensity 
at visual inspection, the adjacent slices available were referred to. Two radiologists (SK, 
KY) interpreted the axial HBP images of 54 patients, and disagreement was resolve by 
consensus. Signal pattern was compared between the groups using ANOVA with post-
hoc test.  
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In the early stages of multistep hepatocarcinogenesis [12,13], some hepatocelllar nodules 
including regenerative nodules (RN), dysplastic nodules (DN), early hepatocellular 
carcinomas (eHCC) or well differentiated hepatocellular carcinomas (wHCC), have been 
known to exhibit high signal intensity on T1WI, either related or unrelated to fatty 
metamorphosis [14-17]. Therefore, there could be a hypothesis that signal intensity before 
contrast administration may influence signal intensity on the postcontrast image. To test this 
hypothesis, we correlated SI on HBP in groups 1 and 2, namely hypo- and hypervascular 
hepatocellular nodules, to the incidence of lesions exhibiting high signal intensity (H) on the 
precontrast THRIVE image using Spearman’s rank correlation. Because fat suppression is 
applied to THRIVE, high signal on precontrast THRIVE indicates non-fatty component with 
short T1 characteristics, such as copper or iron accumulation [14-16]. Also correlated was to 
the presence of fat on CSI, namely presence of signal loss on out-of-phase images [17] as 
compared to in-phase images.      
3. Results 
Among the 65 patients, 10 patients were excluded because these did not meet the incluson 
criteria. In one patient, there were a combined-hepatocellular and cholangiocellular 
carcinoma that were surgically resected and pathologically confirmed, but this was 
excluded because of its too small number that would not tolerate statistical evaluation. 
Finally 154 liver nodules in 54 patients consisted the study population for this study. There 
were 41 men and 13 women, with age ranging from 32 to 92 years old (mean 67). The details 
of the recruited 154 liver masses are as follows: group1 (n=45) 9 were pathologically proven 
by biopsy (4 dysplastic nodules, 2 well-differentiated carcinoma, 1 well to moderately 
differentiated carcinoma) and remaining 37 were clinicoradiologically proven: group 2 
(n=78) 10 were pathologically proven either by biopsy or surgery (3 well differentiated 
carcinoma and 7 moderately differentiated carcinoma) and remaining 68 were 
clinicoradiologically proven: group 3 (n=13) all lesions were proven clinicoradiologicallly: 
group 4 (n=17) all were clinicoradiologically proven (primary lesion for 7 masses was 
colorectal carcinoma, that for 4 was gastrointestinal stromal tumor, that for 3 was breast 
carcinoma, and that for another 3 was renal cell carcinoma): group 5 (n=2) all FNH nodules 
were confirmed clinicoradiologically.  
The details of signal pattern of the four groups are shown in Table 1. There was significant 
difference between the groups (p<0.05, Kruscal-Wallis test). The difference was significant 
between group 5 and other 4 groups (p<0.005, ANOVA with Bonferroni-Dunn’s post-hoc 
test). Namely, the lesions showing high signal intensity on HBP are considered to suggest 
the diagnosis of FNH. None of the FNH nodules in this series had typical central scar. Using 
high signal intensity on HBP as a sign of FNH, 100% sensitivity, 97% specificity, 33% 
positive predictive value, and 100% negative predictive value, were obtained. There were 
one and two lesions that showed high signal intensity on HBP in groups 1 and 2, 
respectively. There was no such lesion in groups 3 and 4. Among these nodules, 
hypovacular hepatic nodule (n=1) can be discriminated from FNH by its hypovascular 
nature (Fig.2). The two lesions in group 2 (hypervascular HCC) can be discriminated from 
FNH by the presence of its fibrous capsule and/or nodule-in-nodule appearance (Figs.3 and 
4). Thus, combining all findings of EOB-MRI, 100% sensitivity, 100% specificity, 100% 
positive and negative predictive values, were achieved. 
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 Group 1
(n=56)
Group 2
(n=78)
Group 3
(n=13)
Group 4
(n=17)
Group 5 
(n=2) 
H 1 2 0 0 2 
I 5 5 3 0 0 
L1 19 21 2 9 0 
L2 16 31 4 0 0 
L3 5 19 4 8 0 
Group 1: hypovascular hepatocellular nodules,  
Group 2: hypervascular hepatocellular carcinoma,     Group 3: hemangioma, 
Group 4: metastasis,     Group 5: focal nodular hyperplasia 
H: higher signal than that of the surrounding liver tissue, 
I: similar signal intensity as that of the liver, 
L1: lower than the liver, but higher than the signal of inferior vena cava (IVC) 
L2: similar signal as that of IVC 
L3: lower signal than that of IVC 
Differences were significant between group5 and groups 1, 2, 3, and 4. ( p<0.005, ANOVA with 
Bonferroni-Dunn’s post-hoc test) 
Table 1. Signal intensity of various liver lesions on hepatobiliary phase images  
4. Discussion 
Qualitative diagnosis on EOB-MR is usually achieved by combining information obtained 
from precontrast conventional MR images (signal intensities on T1WI and T2WI, chemical shift 
imaging, and diffusion-weighted images), and enhancement pattern on the dynamic phase 
images [1,2,4-6]. It is sometimes challenging, however, because of insufficient arterial 
enhancement secondary to the small dose of Gd-EOB-DTPA used (25 μmol/kg) in contrast to 
conventional Gd-based extracellular contrast medium (0.1 mmol/kg). In addition, since 
hepatocellular uptake of Gd-EOB-DTPA occurs shortly after Gd-EOB-DTPA administration 
[1], there is no “equilibrium phase” images on EOB-MR in its strict sense of the word, which 
precludes simple application of our previous diagnostic experience based on Gd-based 
extracellular contrast medium. Our results suggested SI on HBP images may help differentiate 
FNH from other liver nodules, particularly combining findings on other pulse sequences. 
High signal intensity on HBP was suggested to be characteristic to FNH, which is 
concordant to the previous reports [1,6] (Fig.1). Although few, however, there were several 
non-FNH nodules that showed high signal intensity on HBP. High signal intensity of one 
hypovascular hepatocellular nodule may be attributable to high signal intensity on 
precontrast T1-weighted image, which are sometimes observed in dysplatic nodules or early 
HCC, due to cooper or iron deposition [12-14] (Fig.2) or fatty metamorphosis [15]. Because 
EOB uptake have been reported to be almost constant regardless of the grade of HCC, if the 
precontrast signal intensity is high, that would be directly reflected on the SI on HBP [16]. 
The differentiation of this nodule from FNH was easy, because of its hypovascular nature as 
seen on the arterial phase of dynamic study. High SI of two hypervascular HCCs (group 2) 
on HBP may be attributable to its cellular function of Gd-EOB-DTPA uptake, typically 
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known as green hepatoma [17, 18]. One of these two was easily discriminated from FNH by 
the presence of fibrous capsule seen as hypointense rim on the arterial phase image or on 
HBP (Fig.3). The other one was associated with a typical nodule-in-nodule appearance [8], 
which also helped differentiate this from FNH (Fig.4).  
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Fig. 1. 43-year-old asymptomatic woman with minimal liver dysfunction. The mass in the 
left hepatic lobe has remained unchanged for over three years and clinical diagnosis of focal 
nodular hyperplasia (group 5) is made. 
A. Precontrast image of the dynamic study. The lesion exhibited similar or slightly lower 
signal intensity as compared to the surrounding liver tissue (arrow). 
B. Arterial phase image of the dynamic study of gadoxetate (EOB) enhanced MR. The 
lesion is strongly enhanced (arrow). 
C. Hepatobiliary phase image shows homogeneous uptake of EOB within the mass.  
D. Precontrast T2*weighted images (TR/ TE/ FA=266msec /9.2msec /30 degrees) 
revealed an almost isointense or slightly hypointese mass (arrow). 
E. T2* weighted images after administration of superparamagnetic iron oxide (SPIO). The 
signal intensity of the lesion is partially reduced (arrow) suggesting uptake of SPIO. 
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Fig. 2. 58-year-old woman with a histology-proven early hepatocellular carcinoma (group 1) 
who had been followed up for chronic hepatitis C.  
A. Precontrast THRIVE image. A nodule with similar or slightly higher signal as compared 
to the surrounding liver tissue is seen (arrow).  
B. Arterial dominant phase THRIVE image after injection of Gd-EOB-DTPA. No 
significant enhancement is observed (arrow). MDCT obtained at the same period also 
fail to show arterial vascularity (not shown).  
C. Hepatobiliary phase image of THRIVE image. The nodule exhibit almost similar or 
slightly lower signal intensity as compared to the surrounding liver tissue (arrow) 
(I-L1). 
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Fig. 3. 54-year-old man with a clinicoradiologically proven hypervascular hepatocellular 
carcinoma (group 2) which was treated with transarterial chemoembolization. 
A.  Precontrast THRIVE image. A nodule with similar or slightly higher signal as 
compared to the surrounding liver tissue is seen (arrow). 
B. Arterial dominant phase THRIVE image after injection of Gd-EOB-DTPA. Significant 
enhancent is observed (arrow). MDCT obtained at the same period also showed arterial 
enhancement (not shown). Note hypointense fibrous capsule. 
C. Hepatobiliary phase image of THRIVE image. The nodule exhibit higher signal 
intensity than the surrounding liver tissue (arrow) (H). The fibrous capsule is partially 
seen. 
Thus, using combined all findings on EOB-MRI, we could achieve 100% sensitivity, 100% 
specificity, 100% positive predictive value, and 100% negative predictive value, in 
discriminating FNH from other lesions. Our results, however, suggest the difficulty in 
differentiation among other 4 categories using SI on HBP, namely hypovascular hepatocellular 
lesions, hyper vascular HCC, hemangiomas, and metastasis. For the differentiation among 
these entities, findings on other sequences, including dynamic phase images, T2-weighted 
images, diffusion-weighted images, and chemical shift images, may be important. 
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Fig. 4. 75-year-old man with a pathologically proven hypervascular hepatocellular 
carcinoma (group 2). 
＊
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A. Precontrast image. A large heterogeneous mass is seen in the right hepatic lobe. 
B. Arterial dominant phase image after injection of Gd-EOB-DTPA. Significant 
enhancement is observed in the central component of the mass (star), whereas 
peripheral components shows only faint enhancement (arrows).  
C. Late phase image of the dynamic phase. Each component of the mass shows various 
enhancement pattern, resulting in so-called nodule-in-nodule appearance (star and arrows). 
D. Hepatobiliary phase image. The predominant central part shows apparent high signal 
(star) (H).   
There are several limitations in our study, in addition to its retrospective nature. First, the 
biggest limitation is the lack of pathological proof in the majority of the liver masses 
enrolled in this study. Particularly, lesions in groups 1 and 2 are considered quite 
heterogeneous: nodules in group 1 may include DN, eHCC, wHCC, and some RNs and 
mHCC; lesions in group2 may include wHCC, mHCC, and pHCC. The results could have 
been different if only histology-proven lesions are recruited. Another limitation may be the 
adequacy of the use of signal intensity of IVC as a reference tissue to assess the relative 
signal intensity of the liver masses. Because of the possible flow effect, signal intensity of 
IVC could be inconsistent. We therefore measured SI of IVC in the first several patients and 
confirmed there are less than 10% signal difference in IVC between the slices except for the 
edge slices of the scanning slab. This may partly be attributable to the sufficient saturation 
pulse used in THRIVE sequence we used in this study. One needs to be careful of this issue, 
therefore, when other sequence is used for HBP images of EOB-MR, in which spatial 
saturation pulse is insufficient. Other reason for the usage of IVC as reference tissue is that it 
is almost always visualized in the images of the liver and therefore easy to be used for direct 
comparison. Ideally speaking, quantitative measurement of enhancement ratio of HBP 
image vs precotrast images would have been performed, but we preferred practical method 
to evaluate the HPB images which would help differentiate liver nodules in daily practice. 
Third, the time delay of 15 minutes for HBP imaging may be somewhat short as compared 
to the previous reports [1-6]. Because it has been reported that HBP persist from about 10 to 
40 minutes after injection of Gd-EOB-DTPA [1,6], and our preliminary assessment revealed 
no significant difference in the lesion detection between 15 and 20 minutes delay images 
(unpublished data), we adopted 15 minutes delay for HBP in our institute for clinical 
demand in terms of patient through-put. It is still possible, however, that different results 
may be obtained if HBP images were obtained in 20 minutes or even later.  
In conclusion, signal patterns on 15-minute-delay HBP images are different between FNH 
and other liver nodules, including hypovascular hepatocellular nodules, hypervascular 
HCC, hemangiomas, and metastases, and are useful in differentiating these nodules. 
Combining all EOB-MR findings, 100% sensitivity, specificity, positive and negative 
predictive values were achieved in differentiating FNH from non-FNH. 
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